Introduction: The Shifting Paradigm of Takotsubo Syndrome Risk
Takotsubo syndrome (TTS), frequently referred to as ‘broken heart syndrome,’ was once considered a relatively benign, transient condition characterized by reversible left ventricular dysfunction. However, contemporary clinical data have challenged this notion, revealing that the acute phase of TTS carries a risk of life-threatening complications, including cardiogenic shock, malignant arrhythmias, and in-hospital mortality, comparable to those seen in acute coronary syndromes (ACS). Identifying high-risk patients early in the clinical course remains a significant challenge for clinicians in the cardiovascular care unit (CCU).
While various clinical scoring systems, such as the InterTAK Prognostic Score, have been developed to risk-stratify these patients, the search for objective biochemical markers that can enhance predictive accuracy continues. Recent research has turned its focus toward D-dimer, a degradation product of cross-linked fibrin. Traditionally used to rule out venous thromboembolism, D-dimer has emerged as a marker of systemic inflammation and prothrombotic state in several cardiovascular pathologies. A landmark retrospective study recently published in the European Heart Journal: Acute Cardiovascular Care examines the prognostic value of plasma D-dimer levels in patients with TTS, providing critical insights into its role as a predictor of in-hospital mortality.
